ResMed investors sleep soundly | Figma pops 250% on IPO | Ozempic faces a new challenger

ResMed beats full‑year earnings and revenue forecasts thanks to a growth in snorers around the world.

Figma, the design software, has tripled its market value on its IPO debut in one of the biggest first day pops for a US software company ever.

Novo Nordisk, the company behind Ozempic, has seen market value slashed by over €60 billion after investors worry it’s losing the obesity drug race.

_

Download the free app (App Store): http://bit.ly/FluxAppStore

Download the free app (Google Play): http://bit.ly/FluxappGooglePlay  

Daily newsletter: https://bit.ly/fluxnewsletter  

Flux on Instagram: http://bit.ly/fluxinsta  

Flux on TikTok: https://www.tiktok.com/@flux.finance  

—-

The content in this podcast reflects the views and opinions of the hosts, and is intended for personal and not commercial use. We do not represent or endorse the accuracy or reliability of any opinion, statement or other information provided or distributed in these episodes.__

See omnystudio.com/listener for privacy information.